Article Text

Download PDFPDF
Surgery
Treating postoperative pain? Avoid tramadol, long-acting opioid analgesics and long-term use
  1. Georgia C Richards
  1. Center for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  1. Correspondence to Georgia C Richards, Center for Evidence-Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK; georgia.richards{at}phc.ox.ac.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

A recent cohort study investigated ‘the risk of transitioning from acute to prolonged use’ of opioid analgesics in patients undergoing elective surgery. Patients given tramadol or long-acting opioids after discharge were at greater risk of prolonged opioid use than those who were given other short-acting opioids.

EBM verdict

EBM Verdict on: Chronic use of tramadol after acute pain episode: cohort study. BMJ 2019 May 14. doi: 10.1136/bmj.l1849.

  • Long-acting opioids and tramadol should be avoided when discharging patients from hospital after elective surgery. Alternative short-acting opioids at low doses and for short durations are preferable.

Strong pain-relieving medicines called opioids are commonly prescribed when patients are discharged from hospitals. However, pain after elective surgery is usually short-lived. This cohort study1 addresses an important question regarding the prolonged use of opioid analgesics after elective surgery in light of the opioid crisis in the USA and Canada and increased prescribing of opioids in high-income countries.2

Tramadol is both a weak mu-opioid receptor agonist and a serotonin and norepinephrine reuptake inhibitor. Its active metabolite, O-desmethyltramadol, is longer acting than tramadol itself and is a more potent mu-opioid receptor agonist. Responses to tramadol, therefore, vary according to the genotype of the main metabolising enzyme, CYP2D6.3

Tramadol has been available for over 30 years in the UK and for 24 years in the USA (see box 1). It is considered by many to be safer than other opioids. However, deaths from tramadol are increasing.4 Evidence is also emerging that tramadol’s adverse effects are similar to stronger opioids such as fentanyl, which receive stricter regulations by scheduling authorities than tramadol.

Box 1

Brief history of tramadol

1963: Tramadol patented.

1977: Tramadol launched as ‘Tramal’ by Grünenthal GmbH in Germany.

1988: The first tramadol formulation approved by the Medicines and Healthcare products Regulatory Agency in the UK.

1995: Tramadol receives U.S. Food and Drug Administration approval.

2014: Tramadol becomes a controlled substance in both the USA (schedule IV) and the UK (schedule 3, class C).

Two systematic reviews showed that studies in which tramadol was associated with high rates of adverse events were highly susceptible to publication bias.5 Furthermore, patients taking tramadol have the second highest probability of continued opioid use, after those taking long-acting opioids.6

The BMJ cohort study1 retrospectively analysed USA claims data from a large, private insurance health plan. Included participants (n=444 764) had undergone one of 20 commonly performed, elective surgical procedures and were opioid naïve (ie, had not received a prescription for opioids 6 months before the procedure). The exposures were type of discharge prescriptions which were stratified into five mutually exclusive categorises including no opioids (n=86 880, 19.5%), any long-acting opioids (n=5619, 1.3%), tramadol only (n=13 519, 3%), tramadol and other short-acting opioids (n=5457, 1.2%) or short-acting opioids only, excluding tramadol (ie, the reference group, n=333 289, 74.9%). The outcome was risk of prolonged opioid use defined using three definitions: (1) additional opioid use, (2) persistent opioid use and (3) the CONSORT (CONsortium to Study Opioid Risks and Trends) definition of long-term opioid therapy (full definitions are in the footer of table 1).

Table 1

Values of NNTH for prolonged use of opioids after elective surgery

The authors of the BMJ cohort study concluded: “People receiving tramadol alone after surgery had similar to somewhat higher risks of prolonged opioid use compared with those receiving short-acting opioids”. This conclusion is justified, based on the adjusted risk ratios. However, the interpretation of risk ratios can often amplify findings. To improve the interpretation of findings for the clinical setting, for which this study was intended, the number needed to harm (NNTH) is a helpful calculation for comparing treatment groups.

The data from this cohort study1 are abstracted in table 1 with the NNTH. For every 272 (95% CI 171 to 566) patients who receive a discharge prescription for tramadol alone, one will continue to use opioids for 90 or more days over 180 days after surgery. The NNTH for patients discharged taking any long-acting opioid is significantly lower (NNTH=31, 95% CI 26 to 37). Short-acting opioids in the setting of acute pain are, therefore, preferable to both long-acting opioids and tramadol when discharging patients after elective surgery.

Confounding and selection biases are the two important aspects to consider in this cohort study. The authors suggested confounding was addressed by including participants with ‘minimal clinical complexity’.1 Although the adjusted risk ratios did take into account various confounding factors including type of surgery and morphine equivalent dose at discharge, the comparison groups are not identical in nature. Thus, other factors such as the duration of discharge prescription may also be associated with the prolonged use of opioids following elective surgery.

Limitations of the cohort study1 highlight the inability of large datasets to ascertain the reason patients receive additional opioid prescriptions and other benefits and/or harms that patients experience from opioids that would further contribute to informed decisions. The latter are particularly important since there is a paucity of data to allow accurate quantification of the risks of using tramadol in people with acute pain.5 Although hydrocodone and short-acting oxycodone are the two most commonly prescribed opioids, their potential for long-term use after surgery was not evaluated in this study. This analysis would have provided further insight into the problem of prolonged opioid use.

Tramadol remains poorly regulated in low-income countries and receives lower scheduling in high-income countries. Despite the need for additional research into the clinical benefits and harms of tramadol, the evidence from this study of the greater risk of prolonged use of tramadol should be considered by scheduling authorities and in clinical guidelines for acute pain.

References

Footnotes

  • Contributors GCR wrote and edited the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests GCR is reading for the degree of Doctor of Philosophy on the prescribing of opioid analgesics in primary care, funded by the National Institute for Health Research School for Primary Care Research Doctoral Studentship, the Naji Foundation and the Rotary Foundation.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.